Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT shares tumble on Q2 results

August 1, 2018 By Sarah Faulkner

Intersect ENTShares in Intersect ENT (NSDQ:XENT) fell today after the medical device maker missed sales expectations on Wall Street with its second-quarter financial results.

The Menlo Park, Calif.-based company posted a net loss of -$4.2 million on sales of $26.3 million for the 3 months ended June 30, for sales growth of 9.7% compared with the same period last year.

Earnings per share were -14¢, ahead of consensus on The Street. But the company fell short on sales estimates – analysts were looking for sales of $28.2 million.

“We are gratified by the initial response of patients and physicians to Sinuva, with over 325 patients treated through the second quarter. We are also pleased with the rate of payor coverage and believe that these factors, combined with our strong clinical evidence, reinforce the significant potential of Sinuva,” president & CEO Lisa Earnhardt said in prepared remarks.

“We are meeting the challenges of the launch by taking action including expanding and leveraging the reimbursement hub and growing our sales and reimbursement teams. We remain convinced that Sinuva has a bright future and that, with these measures in place, we will be in a position to expand our launch and continue to grow Propel,” Earnhardt added.

Intersect ENT said it expects to post sales of $106 million to $109 million for the full year, down from its previous guidance of $113 million to $115 million.

XENT shares were trading at $27.45 apiece today in mid-morning activity, down -15.2%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Proteus Digital Health restructuring amid reported funding woes
  • Dexcom warns of potential danger to European app users
  • Report: 3M may sell off its drug-delivery business for $1 billion
  • W.L. Gore officials think they can spur insulin delivery system innovation
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS